Elicio reports Q1 net loss of $11.2M; cash into Q4 2025; Phase 2 interim analysis Q3 2025

Elicio Therapeutics, Inc.

2025-Q1 EPS reported -$0.87

Net loss of $11.2M ($0.87 per share) for Q1 2025 vs $11.8M ($1.15) in Q1 2024.
R&D expense $7.8M, G&A $3.0M; cash and equivalents $18.4M at March 31, 2025.
DFS event-driven interim analysis of Phase 2 AMPLIFY-7P trial (ELI-002 in PDAC) expected in Q3 2025.
FDA alignment on key design elements of planned Phase 3 study for ELI-002 in resected mKRAS PDAC.
Appointed Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer in March 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.